MSReactor: measuring thinking and memory over time
26 August 2025
People living with MS find MSReactor is a convenient and acceptable way to monitor changes in their thinking and memory over time.
People living with MS find MSReactor is a convenient and acceptable way to monitor changes in their thinking and memory over time.
The Pharmaceutical Benefits Advisory Committee has recommended subcutaneous ocrelizumab (Ocrevus®) be listed on the PBS for treating relapsing remitting MS.
The Government has announced changes to the NDIS aimed at slowing growth and making the scheme more sustainable. What are those changes and how will they impact Australians living with MS?
MS Australia announces the four recipients of the first round of Incubator Grants for 2025.
A world-first Australian study is using DNA to identify a person’s genetic risk of developing multiple sclerosis (MS) to understand how their immune system responds to a common virus linked to the disease.Â
MS Australia is calling on the government to improve the aged care system to better meet the needs of older people with disability and reaffirm their commitment to reduce wait times for home care packages.
CEO Rohan Greenland reveals the upcoming launch of a national blueprint for neurological conditions, designed to prompt the Australian Government to finally deliver an action plan for the 7 million Australians affected.
Consistently high antibodies to a specific protein of the Epstein-Barr virus may predict MS years before disease onset.
The Pharmaceutical Benefits Advisory Committee has recommended ublituximab (Briumvi®) be listed on the PBS for treating relapsing remitting MS.